By CD Media Staff | February 25, 2020

First Coronavirus Vaccine Delivered For Testing...New Drug Treatments On Horizon
Spread of Coronavirus COVID-19 by Comasco Mapper 24-02-2020
Image by Dany Crash

President Trump said today the coronavirus outbreak was not yet a serious event for the United States and that things were ‘under control’.

“I think it’s a problem that’s going to go away,” Trump declared.

Trump also reportedly told a group of executives gathered in India that the US has “essentially closed the borders” (well, not really) and that “we’re fortunate so far and we think it’s going to remain that way,” reported CNN.

Democrats beg to differ and made light of Trump’s $2.5 billion spending package to combat the epidemic.

Drugmaker Moderna Inc. has shipped the first batch of its rapidly developed coronavirus vaccine to U.S. government researchers, who will launch the first human tests of whether the experimental shot could help suppress the epidemic originating in China, reported the Wall Street Journal

Do you think President Biden should be impeached for the crisis in Afghanistan and loss of American lives?

By completing the poll, you agree to receive emails from SteveGruber.com, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.

“Going into a Phase One trial within three months of getting the sequence is unquestionably the world indoor record. Nothing has ever gone that fast,” said the CDC’s Dr. Fauci on CNBC.

China will release results at the end of April from clinical trials of a Gilead Sciences Inc. drug that is emerging as a frontrunner in the race to find an effective treatment for the novel coronavirus, reported Bloomberg.

The outcome of trials of the experimental medication remdesivir on 761 patients in Wuhan, the city where the virus originated, will be made public on April 27, China’s National Intellectual Property Administration said Tuesday.

This piece originally appeared on CreativeDestructionMedia.com and is used by permission.

The opinions expressed by contributors and/or content partners are their own and do not necessarily reflect the views of Steve Gruber.